ODAC To Consider Whether Genasense Requires Additional Study For Melanoma Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis/Genta Genasense for advanced malignant melanoma failed to show an overall survival benefit but appeared to extend progression-free survival. FDA tells committee that progression-free survival has not historically served as basis for approval.